Glucotrack (GCTK) furnishes Regulation FD press release in 8-K filing

Rhea-AI Filing Summary

Glucotrack, Inc. furnished a press release under Regulation FD on November 3, 2025. The company submitted the release as Exhibit 99.1 to a current report, using it to provide public information in a way that treats investors fairly. The exhibit is designated as “furnished,” meaning it is not deemed filed for liability purposes under Section 18 of the Exchange Act unless specifically stated otherwise.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001506983 0001506983 2025-11-03 2025-11-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 3, 2025

GLUCOTRACK, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41141		98-0668934
(State or Other Jurisdiction		(Commission		(IRS Employer
of Incorporation)		File Number)		Identification No.)

301 Rte. 17 North, Ste. 800, Rutherford, NJ		07070
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (201) 842-7715

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		GCTK		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On November 3, 2025, Glucotrack, Inc., a Delaware corporation (the “Company”), issued a press release (the “Press Release”). The Press Release is furnished herewith as Exhibit 99.1.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated November 3, 2025
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 3, 2025
	GLUCOTRACK, INC.
	By:	/s/ Paul Goode
	Name:	Paul Goode
	Title:	Chief Executive Officer

FAQ

What did Glucotrack, Inc. (GCTK) disclose in this 8-K filing?

Glucotrack, Inc. furnished a press release as part of a current report. The company used Item 7.01 (Regulation FD Disclosure) and attached the release as Exhibit 99.1 to share information with the market.

What is the purpose of Item 7.01 Regulation FD Disclosure for GCTK?

Item 7.01 allows Glucotrack, Inc. to share information publicly under Regulation FD. It helps ensure all investors receive the same information at the same time through a furnished press release exhibit.

Is Glucotrack’s November 3, 2025 press release considered filed with the SEC?

The press release is treated as furnished, not filed, under the Exchange Act. It is not subject to Section 18 liabilities unless Glucotrack, Inc. specifically states it should be considered filed or incorporates it into another filing.

Which exhibit did Glucotrack, Inc. attach to its November 3, 2025 8-K?

Glucotrack, Inc. attached Exhibit 99.1, a press release dated November 3, 2025. The filing also includes Exhibit 104, which is the cover page interactive data file embedded within the inline XBRL document.

Who signed the November 3, 2025 Glucotrack, Inc. 8-K filing?

The 8-K was signed on behalf of Glucotrack, Inc. by Paul Goode. He signed in his capacity as Chief Executive Officer, acting as the duly authorized officer for the company.

On what date did Glucotrack, Inc. issue the press release attached to this 8-K?

Glucotrack, Inc. issued the press release on November 3, 2025. That same date appears both as the date of the press release itself and as the date of the current report signature.